Gene composition for HR+ / HER2 + breast cancer immunohistochemical typing and application thereof

By screening out four genes, CD8A, KRT5, GFRA1 and PFKP, combined with immunohistochemistry technology, an immunohistochemical classification method for HR+/HER2+ breast cancer was constructed, solving the problems of high typing costs and complexity in the existing technology. , realizes simple and efficient classification and individualized treatment guidance.

CN118932060AInactive Publication Date: 2024-11-12SHENGJING HOSPITAL OF CHINA MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411127911.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, the molecular typing method of HR+/HER2+ breast cancer has high costs, complex process flow and potential batch effects, resulting in a reduced feasibility in clinical application and promotion, and lacks simple, efficient and accurate Classification methods to guide individualized treatment.

Method used

Using an immunohistochemistry-based classification system, the four genes, CD8A, KRT5, GFRA1 and PFKP, were screened as gene compositions, and combined with immunohistochemistry technology, an immunohistochemical classification method for HR+/HER2+ breast cancer was constructed to replace complex The expensive gene expression profiling sequencing technology enables simple and efficient molecular typing.

Benefits of technology

Provides a low-cost, easy-to-operate and highly consistent immunohistochemical classification method for breast cancer, which can accurately classify and guide individualized treatment, reduces the economic and time cost of the classification process, and improves clinical Feasibility of application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932060A_ABST
    Figure CN118932060A_ABST
Patent Text Reader

Abstract

The invention relates to a gene composition for HR < + > / HER2 < + > breast cancer immunohistochemical typing and application thereof. The gene composition for HR < + > / HER2 < + > breast cancer immunohistochemical typing comprises the following four genes: a CD8A gene, a KRT5 gene, a GFRA1 gene and a PFKP gene, the HR < + > / HER2 < + > breast cancer immunohistochemical typing result provided by the invention has high consistency with a gold standard RNA sequencing-based molecular typing result, and has guiding significance for clinical treatment of patients, each immunohistochemical subtype has different molecular characteristics, and potential treatment possibility is prompted, so that the HR < + > / HER2 < + > breast cancer immunohistochemical typing method has a wide application prospect. A foundation is provided for clinical application of HR < + > / HER2 < + > breast cancer subtype specific treatment, and the problems that HR < + > / HER2 < + > breast cancer typing operation is complex, sample availability is poor, consumed time and cost are high, and the batch effect is large are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of clinical application of cancer typing, transcriptomics and immunohistochemical detection technology, and in particular to a gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer and an application thereof. Background Art

[0002] Human epidermal growth factor receptor-2 (HER2) positive breast cancer refers to breast cancer with overexpression of HER2, accounting for 15%-20% of breast cancer. HER2 overexpression is the main driving factor for the occurrence and progression of HER2-positive breast cancer and an important adverse prognostic factor for breast cancer. Hormone receptor (HR) positive, HER2 positive breast cancer refers to breast cancer with positive estrogen receptor (ER) or progesterone receptor (PR) and overexpression of HER2. Different from HR- / HER2+ breast cancer, HR+ / HER2+ breast cancer is more heterogeneous and has unique molecular biological behavior.

[0003] Accurate classification of HR+ / HER2+ breast cancer based on gene expression profiles is essential for revealing the molecular nature of this highly heterogeneous disease and guiding personalized treatment. However, this model has not been widely used to guide treatment in clinical practice. The main challenges in conducting such clinical studies include high costs, complex process flows, and potential batch effects. Therefore, a simplified method is needed to accurately classify HR+ / HER2+ breast cancer so that it can be used in clinical neoadjuvant therapy practice to improve the pathological response (pCR) rate.

[0004] Although the molecular typing of HR+ / HER2+ breast cancer given by mRNA expression spectrum sequencing can simultaneously reveal the biological characteristics of HR+ / HER2+ breast cancer, and suggest subtype-specific treatment strategies, the gene expression spectrum sequencing technology is expensive, the technical process is complex, and the batch effect is large, which leads to its clinical application and the feasibility of promotion is greatly reduced. Therefore, it is urgent to find an alternative method that can be clinically simple, efficient and more accurately realize the molecular typing of HR+ / HER2+ breast cancer. Considering that in all breast cancers, there is a precedent of using immunohistochemistry (or fluorescence in situ hybridization) technology to detect ER, PR, HER2 and Ki67 to molecularly type breast cancer, from this to that, for HR+ / HER2+ breast cancer, the inventors also attempt to construct a set of typing systems based on immunohistochemistry, replacing complex and expensive expression spectrum sequencing technology, so as to realize the molecular typing of HR+ / HER2+ breast cancer clinically, and then realize the individualized treatment of HR+ / HER2+ breast cancer.

[0005] At present, there is no recognized HR+ / HER2+ breast cancer immunohistochemical typing scheme in clinical practice. The molecular typing method of breast cancer based on high-throughput sequencing and expression profile clustering requires a lot of time and economic costs. Therefore, there is an urgent need for a clinical HR+ / HER2+ breast cancer typing method that can be used to simply and efficiently perform HR+ / HER2+ breast cancer molecular typing for any clinical HR+ / HER2+ breast cancer patient, indicating their genomic characteristics and individualized treatment strategies. Summary of the invention

[0006] In view of the deficiencies of the prior art, the purpose of the present invention is to provide a gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer and its application, which can easily and efficiently perform HR+ / HER2+ breast cancer molecular typing for any clinical HR+ / HER2+ breast cancer patient, and indicate their genomic characteristics and individualized treatment strategies.

[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer, comprising the following four genes: CD8A gene, KRT5 gene, GFRA1 gene and PFKP gene.

[0009] As an optional method, in the above gene composition, the method for immunohistochemical typing of HR+ / HER2+ breast cancer is:

[0010] CD8A positive, any KRT5, GFRA1 and PFKP expression: immunohistochemical MUKDEN type III; CD8A negative, KRT5 positive, any GFRA1 and PFKP expression: immunohistochemical MUKDEN type IV; CD8A negative, KRT5 negative, GFRA positive, any PFKP expression: immunohistochemical MUKDEN type II; CD8A negative, KRT5 negative, GFRA negative, PFKP negative expression: immunohistochemical MUKDEN type I;

[0011] Among them, CD8A positivity was defined as the percentage of CD8A-positive tumor cells in all cells ≥20%; KRT5 positivity was defined as the percentage of KRT5-positive tumor cells in all tumor cells ≥10%; GFRA positivity was defined as the percentage of GFRA-positive tumor cells in all tumor cells ≥10%; PFKP positivity was defined as the percentage of PFKP-positive tumor cells in all tumor cells ≥10%.

[0012] In a second aspect, the present invention provides a method for screening the gene composition described in the first aspect, wherein the gene composition is screened by the following steps:

[0013] Step S1: Perform differential gene analysis between subtypes of HR+ / HER2+ breast cancer with mRNA expression profile data, identify highly expressed genes in each subtype, and conduct preliminary screening of differential genes, including 70 MUKDEN I-specific genes, 95 MUKDEN II-specific genes, 388 MUKDEN III-specific genes, and 520 MUKDEN IV-specific genes;

[0014] Step S2: using the mRNA expression data and mass spectrometry protein expression data from the Cancer Genome Atlas database, complete the Pearson correlation analysis between mRNA expression level and protein expression level;

[0015] Step S3: Through KEGG pathway enrichment, select the gene sets enriched in the characteristic pathways in each subtype, and take the intersection of the gene sets with positive correlation between mRNA level and protein level in the Pearson correlation analysis results;

[0016] Step S4: Literature research was conducted on the above intersection gene sets. PFKP gene and GFRA1 gene were selected as candidate characteristic genes for immunohistochemical testing for MUKDEN I and MUKDEN II subtypes, respectively. CD8A gene and KRT5 gene were selected for immunohistochemical testing for MUKDEN III and MUKDEN IV subtypes based on comprehensive consideration of pathway characteristics and clinical immunohistochemical antibody accessibility;

[0017] Step S5: The gene combination finally screened out for immunohistochemical typing of HR+ / HER2+ breast cancer is CD8A gene, KRT5 gene, GFRA1 gene and PFKP gene.

[0018] As an optional manner, in the above screening method, in the step S1, the differential gene analysis between subtypes uses the Limma package of R language, and the initial screening of differential genes is based on Log2 (fold change) ≥ 1.0 and corrected P value < 0.05 as the standard.

[0019] As an optional manner, in the above screening method, in step S2, the Pearson correlation analysis uses the correlation coefficient ≥ 0.7 and the correlation test P value < 0.05 as the standard to further screen and filter the differentially expressed genes.

[0020] As an optional manner, in the above screening method, in step S3, among the characteristic pathways of each subtype, MUKDEN I type is specifically activated by the hypoxia pathway, MUKDEN II type is specifically activated by the estrogen receptor-related pathway, MUKDEN III type is prominent in tumor immune-related characteristics, and MUKDEN IV type is prominent in tumor matrix characteristics.

[0021] In a third aspect, the present invention provides use of the gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer described in the first aspect in the preparation of a HR+ / HER2+ breast cancer typing detection kit.

[0022] As an optional mode, in the above application, the kit includes a biomarker, and the biomarker is the gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer as described in the first aspect above.

[0023] As an optional manner, in the above application, the biomarker is a nucleic acid, an oligonucleic acid chain, a PCR primer set or an antibody. Preferably, the biomarker is an antibody to the protein expressed by the gene composition.

[0024] In a fourth aspect, the present invention provides use of the kit described in the third aspect in preparing a preparation for diagnosing HR+ / HER2+ breast cancer or predicting the prognosis of HR+ / HER2+ breast cancer.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] (1) There is currently no recognized immunohistochemical typing method for HR+ / HER2+ breast cancer. Based on the transcriptome data set of 131 HR+ / HER2+ breast cancer patients, the present invention screened out PFKP gene, GFRA1 gene, CD8A gene and KRT5 gene as genes for immunohistochemical typing of HR+ / HER2+ breast cancer, constructed an immunohistochemical typing method for HR+ / HER2+ breast cancer, and verified it in existing HR+ / HER2+ breast cancer tissue samples;

[0027] (2) The results of the immunohistochemical typing of HR+ / HER2+ breast cancer provided by the present invention are highly consistent with the gold standard molecular typing results based on RNA sequencing. The immunohistochemical typing of the present invention has guiding significance for the clinical treatment of patients. The different molecular characteristics of each immunohistochemical subtype suggest potential treatment possibilities, which provides a basis for the clinical application of HR+ / HER2+ breast cancer subtype-specific treatment;

[0028] (3) The present invention solves the problems of complex operation, poor sample availability, time-consuming and high cost, and large batch effect in HR+ / HER2+ breast cancer typing by expression profiling sequencing technology. The cost of typing using mRNA expression profiling sequencing is 4,000-5,000 yuan per patient, while the immunohistochemical typing method described in the present invention only costs 400-500 yuan per patient, and the typing results are highly consistent and reproducible, which is very suitable for clinical application and promotion. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 It is the overall process of screening immunohistochemical typing from HR+ / HER2+ breast cancer mRNA typing.

[0030] Figure 2 It is the typing and characteristic diagram of HR+ / HER2+ breast cancer based on mRNA level in the implementation of the present invention.

[0031] Among them, A: a heat map describing the mRNA level expression profiles of the four subtypes in the 131 samples of the training set, and a validation heat map of 139 HR+ / HER2+ breast cancer samples in the TCGA database and 156 HR+ / HER2+ breast cancer samples from the I-SPY series of clinical trials in the GEO database; BC: shows the correspondence between the subtypes of the training set and the two validation sets (B represents the TCGA cohort, and C represents the GEO cohort). The significant relationship between the subtypes is represented by the Bonferroni-adjusted p value, showing that there is a significant association between the subtypes in red, and no association in blue; D: a radar chart represents the normalized enrichment score (NES) of the characteristic pathway after GSEA analysis in each subtype; E: a heat map describing the abundance of immune cells and stromal cell populations in MUKDEN I, II, III and IV subtypes.

[0032] Figure 3 This is the expression and differential analysis of the mRNA levels of four factors, PFKP (A), GFRA1 (B), CD8A (C), and KRT5 (D), in the four subtypes of MUKDEN in 131 transcriptome sequencing data.

[0033] Figure 4 This is a correlation analysis between the expression of four factors PFKP (A), GFRA1 (B), CD8A (C), and KRT5 (D) at the mRNA level and their protein expression in TCGA public data.

[0034] Figure 5 It is the evaluation standard of immunohistochemical staining of four factors, CD8A, KRT5, GFRA1, and PFKP (the intensity is negative, weakly positive, and strongly positive, respectively; the scale bar is 100 μm).

[0035] Figure 6 This is the immunohistochemical analysis process and typing results of 60 patients.

[0036] Figure 7 κ analysis was used to evaluate the consistency between the immunohistochemistry-based classification and the mRNA-based classification. The overall Cohen's κ coefficient was 0.727, with good consistency. According to the matrix on the right, it can be concluded that the proportion of samples classified into the same subtype by the two classification methods was 80%.

[0037] Figure 8 H&E staining of Tils in each subtype and comparison of Tils expression levels in four MUKDEN subtypes. Scale bar is 100 μm. DETAILED DESCRIPTION

[0038] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0039] Embodiment 1:

[0040] The gene combination used for immunohistochemical typing of HR+ / HER2+ breast cancer in the present invention is CD8A gene, KRT5 gene, GFRA1 gene and PFKP gene. The specific screening method comprises the following steps (detailed process as shown in Figure 1 shown):

[0041] Step S1: Perform differential gene analysis among subtypes of HR+ / HER2+ breast cancer with mRNA expression profile data, identify highly expressed genes in each subtype, and perform preliminary screening of differential genes;

[0042] Specifically, based on the mRNA expression profile sequencing data of 131 HR+HER2+ breast cancer patients from Shengjing Hospital Affiliated to China Medical University, and the mRNA molecular typing results obtained by expression profile clustering, the Limma package of R language was first used to perform differential gene analysis to find out the highly expressed genes of each subtype, and the initial screening of differential genes was performed with Log2 (fold change) ≥ 1.0 and corrected P value < 0.05 as the standard (data not shown);

[0043] Step S2: using the mRNA expression data and mass spectrometry protein expression data from the Cancer Genome Atlas database, complete the Pearson correlation analysis between mRNA expression level and protein expression level;

[0044] Specifically, the mRNA sequencing data and mass spectrometry protein expression data from the Cancer Genome Atlas (TCGA) database were used to perform Pearson correlation analysis between mRNA expression levels and protein expression levels, and the differentially expressed genes were further screened and filtered using a correlation coefficient ≥ 0.7 and a correlation test P value < 0.05 as the standard.

[0045] Step S3: Through KEGG pathway enrichment, select the gene sets enriched in the characteristic pathways in each subtype, and take the intersection of the gene sets with positive correlation between mRNA level and protein level in the Pearson correlation analysis results;

[0046] Specifically, through KEGG pathway enrichment, we selected the characteristic pathways of each subtype, in which MUKDEN I type was specifically activated by the hypoxia pathway, MUKDEN II type was specifically activated by the estrogen receptor-related pathway, MUKDEN III type was prominent in tumor immune-related characteristics, and MUKDEN IV type was prominent in tumor stroma characteristics;

[0047] Step S4: Literature research was conducted on the above intersection gene sets. PFKP gene and GFRA1 gene were selected as candidate characteristic genes for immunohistochemical testing for MUKDEN I and MUKDEN II subtypes, respectively. CD8A gene and KRT5 gene were selected for immunohistochemical testing for MUKDEN III and MUKDEN IV subtypes based on comprehensive consideration of pathway characteristics and clinical immunohistochemical antibody accessibility (CD8A gene is crucial in tumor immunity, and KRT5 is closely related to matrix components);

[0048] Specifically: by integrating the pathway feature information of each subtype and the expression of differential factors at the transcriptome level, four indicators were screened out, and 60 tumor sections were immunohistochemically stained to distinguish the four subtypes; finally, the immunohistochemical-based typing and transcriptome-based typing were tested for consistency, and the overall Cohen's κ coefficient was 0.727 (95% CI, 0.589-0.864), which showed that there was a high consistency between the two classifiers; considering the pathway characteristics of each subtype and the accessibility of clinical immunohistochemical antibodies, the typing genes for immunohistochemistry were selected; the antibodies used for immunohistochemical staining are shown in Table 1 below:

[0049] Table 1 Antibodies used for immunohistochemical staining

[0050] Immunohistochemical molecules Antibody code company Dilution multiple CD8A KHC0014 CST Ready to use KRT5 Bs-20824R Bo Ao Sen 1:200 GFRA1 Bs-0201R Bo Ao Sen 1:200 PFKP 13389-1-AP PTG 1:200

[0051] Step S5: The genes finally screened out for immunohistochemical typing of HR+ / HER2+ breast cancer are CD8A gene, KRT5 gene, GFRA1 gene and PFKP gene;

[0052] Specifically: Through the permutation and combination of the immunohistochemical expression of the four factors, 60 cases of HR-positive and HER2-positive breast cancer were divided into the following subtypes:

[0053] (1) IHC-III: CD8A positive (+);

[0054] (2) IHC-IV type: CD8A negative (-) and KRT5 positive (+);

[0055] (3) IHC-II type: CD8 negative (-), KRT5 negative (-) and GFRA1 positive (+);

[0056] (4) IHC-I type: CD8 negative (-), KRT5 negative (-), GFRA1 negative (-) and PFKP positive (+).

[0057] The method for immunohistochemical typing of HR+ / HER2+ breast cancer is:

[0058] CD8A positive, any KRT5, GFRA1 and PFKP expression: immunohistochemical MUKDEN type III;

[0059] CD8A negative, KRT5 positive, any GFRA1 and PFKP expression: immunohistochemical MUKDEN type IV;

[0060] CD8A negative, KRT5 negative, GFRA positive, any PFKP expression: immunohistochemical MUKDEN type II;

[0061] CD8A negative, KRT5 negative, GFRA negative, PFKP negative expression: immunohistochemical MUKDEN type I;

[0062] Among them, CD8A positivity was defined as the percentage of CD8A-positive tumor cells in all cells ≥20%; KRT5 positivity was defined as the percentage of KRT5-positive tumor cells in all tumor cells ≥10%; GFRA positivity was defined as the percentage of GFRA-positive tumor cells in all tumor cells ≥10%; PFKP positivity was defined as the percentage of PFKP-positive tumor cells in all tumor cells ≥10%.

[0063] Embodiment 2:

[0064] 1. Breast cancer patient specimens

[0065] The present invention uses tumor tissue puncture samples from patients with HR-positive and HER2-positive breast cancer before neoadjuvant therapy for experiments. All patients were diagnosed with invasive ductal carcinoma by pathological puncture, and molecular typing was HR-positive and HER2-positive breast cancer. The samples included 131 HR-positive and HER2-positive breast cancer tumor puncture tissue specimens, of which 96 received neoadjuvant therapy.

[0066] 2. Unsupervised clustering based on sequencing data

[0067] The non-negative matrix algorithm (NMF function in R software) was used to identify differentially expressed genes in HR-positive and HER2-positive breast cancer transcriptome sequencing data sets to separate clusters and determine the optimal number of clusters. The correlation coefficient was maximized to select the optimal number of clusters for subsequent analysis. The top 20% genes in the absolute median deviation (MAD) were selected for unsupervised clustering.

[0068] 3. Subtype characteristics and prediction of HR-positive and HER2-positive breast cancer

[0069] Differential expression analysis was performed between each MUKDEN subtype. Genes with log2 FC ≥ 1 and corrected P < 0.05 were defined as characteristic differential genes. Functional and pathway enrichment analysis was performed using the Clusterprofiler package of R software, and the significance threshold was set at P < 0.05. The nearest template prediction (NTP) analysis of the GenePattern website was used to predict HR-positive and HER2-positive breast cancer data in the TCGA and GEO cohorts. The subclass mapping (SubMap) algorithm uses the gene set enrichment analysis (GSEA) function to evaluate the degree of commonality of different subtypes in independent data sets. The predicted classification results in public data sets (TCGA and GEO) were compared with our classification results. The P value is used to evaluate the similarity. The lower the P value, the higher the similarity ( Figure 2 AC).

[0070] 4. Differential genes and characteristic pathways in treatment subgroups

[0071] The KEGG and GSEA databases were used to analyze the enriched pathways in each subtype. KEGG and GSEA analyses were performed on each transcriptome subtype using the ClusterProfiler package of R software. GSEA evaluates and determines whether a set of a priori defined genes show statistically significant associations with specific phenotypic cumulative changes in gene expression. ES calculation in GSEA is as follows: First, the genes are ranked from highest to lowest importance, and then the entire ranked list is used to evaluate the distribution of genes in each gene set ( Figure 2 D).

[0072] 5. Estimation of the number of immune cells in tumor tissue

[0073] The Microenvironment Cell Population Counter (MCP Counter) is a method based on gene expression profiling data to assess the absolute abundance of eight immune and two non-immune stromal cell populations (immune cell populations: T cells, CD8+ T cells, natural killer cells, cytotoxic lymphocytes, B cell lineage, monocyte lineage cells, myeloid dendritic cells, and neutrophils; stromal cell populations: endothelial cells and fibroblasts). Figure 2 E).

[0074] 6. Screening of Immunohistochemical Typing Genes

[0075] In order to establish an immunohistochemical-based accurate classification method for HR-positive and HER2-positive breast cancer that is easy to implement in clinical practice, the genes highly expressed at the mRNA level in each subtype were first identified through differential expression analysis. Then, according to the unique biological characteristics of each subtype, the genes enriched in typical pathways were summarized. The degree and location of immunohistochemical staining of candidate factors in breast tumors were determined based on the results of correlation analysis of mRNA and protein expression in public databases, literature research, and querying the Human Protein Atlas database.

[0076] The characteristic pathway of the hypoxic subtype is HIF-1. In the characteristic gene typing, the genes enriched in this pathway are ERBB2 and PFKP. However, the subtypes studied by the inventors are all HR-positive and HER2-positive. ERBB2 is not conducive to distinguishing new subtypes, so PFKP is selected as the immunohistochemical staining factor of MUKDENⅠ type.

[0077] The characteristic pathway of the endocrine-sensitive type is the ER pathway, but like the ERBB2 gene, the ER factor does not have the ability to distinguish this subtype, so factors were selected from the genes with the largest difference folds. Combined with literature research and expression location information, GFRA1 was finally determined as the immunohistochemical staining factor for MUKDEN type II.

[0078] The immunoregulatory subtype has highly expressed immune-related molecules. CD8, as an effector T cell, is an important factor in immune regulation. Based on the comprehensive consideration of pathway characteristics and clinical immunohistochemical antibody accessibility, CD8A was selected as the indicator of MUKDEN type III.

[0079] The internal characteristics of the highly heterogeneous subtype are complex, involving many pathways, and it is difficult to select characteristic factors that can represent all pathways. However, through the immune infiltration analysis mentioned above, it was found that this type of tumor stroma is richly expressed. For the immunohistochemical staining experience of the stroma, the commonly used indicators in clinical work are CK5 / 6, and the corresponding gene is KRT5. Finally, GFRA1, KRT5, PFKP, and CD8A were selected as candidate factors ( Figure 1 ) and evaluated the expression of PFKP, GFRA1, CD8A, and KRT5 at the mRNA level in 131 samples of MUKDEN subtype ( Figure 3 At the same time, the correlation between mRNA level and protein level of these four factors was evaluated through the TCGA database ( Figure 4 ).

[0080] 7. Immunohistochemical staining and typing strategy

[0081] Immunohistochemical staining of paraffin-embedded sections of 60 HR-positive and HER2-positive breast cancer biopsy or intraoperative specimens with known MUKDEN subtypes was performed, and negative and positive controls were set up ( Figure 5 ). Next, an IHC-based classification method was developed. First, the priority of the four markers in the classification method was determined based on their mRNA expression. From the mRNA expression level, it can be seen that the difference in CD8A is the most obvious, so type III was first screened out through CD8A; GFRA1 cannot effectively distinguish between type II and type IV (P>0.05), but KRT5 can distinguish type IV, so the second step is to perform KRT5 factor staining to screen type IV, and then use GFRA to screen type II. Finally, 60 cases of HR-positive and HER2-positive breast cancer were divided into the following subtypes ( Figure 6 ): (1) IHC-III: CD8A positive (+); (2) IHC-IV: CD8A negative (-) and KRT5 positive (+); (3) IHC-II: CD8 negative (-), KRT5 negative (-) and GFRA1 positive (+); (4) IHC-I: CD8 negative (-), KRT5 negative (-), GFRA1 negative (-) and PFKP positive (+).

[0082] 8. Consistency assessment between IHC-based and mRNA-based typing

[0083] κ analysis was performed to assess the agreement between the IHC-based classification and the mRNA-based classification. The overall Cohen's κ coefficient was 0.727 (95% CI, 0.589-0.864), which indicated a good agreement between the two classifiers ( Figure 7 ). The proportion of samples classified into the same subtype by the two classification methods was 80%. In addition, the κ coefficient of each subtype was calculated. The two classification methods showed the highest consistency in the classification of HR-positive and HER2-positive breast cancer, which was the immunoregulatory subtype (κ=0.883; 95% CI, 0.756-1.038). In the classification of HR-positive and HER2-positive breast cancer, the two classification methods were basically consistent with the endocrine subtype (κ=0.762; 95% CI, 0.584-0.940) and hypoxic subtype (κ=0.712; 95% CI, 0.497-0.977). The consistency of HR-positive and HER2-positive breast cancer classification into highly heterogeneous subtypes was moderate (κ=0.522; 95% CI, 0.276-0.768).

[0084] 9. Assessment of Tumor Infiltrating Lymphocytes (TIL)

[0085] Tumor infiltrating lymphocytes were assessed on H&E-stained sections of tumors. Intratumoral TILs (iTILs) were defined as lymphocytes in tumor nests, while stromal TILs (sTILs) were defined as lymphocytes in the stroma between tumor nests ( Figure 8 ).

[0086] 10. Data Processing and Statistical Analysis

[0087] All statistical analyses were performed using R software, version 4.2.2. The independent sample T test was used for comparison between groups of measurement data; the chi-square test or Fisher's exact test was used for comparison between groups of count data. All statistical analysis methods used two-sided tests, ns means not significant, that is, statistically insignificant; P < 0.05 is considered to be statistically significant, * represents P < 0.05, ** represents P < 0.01, and *** represents P < 0.001.

[0088] In summary, the inventor team of Shengjing Hospital Affiliated to China Medical University established a transcriptome cohort of 131 HR+ / HER2+ breast cancer patients, and established four new molecular subtypes by unsupervised clustering. Through pathway enrichment analysis methods such as KEGG and GSEA, the biological characteristics of each of the four molecular subtypes were explored and verified in external public data sets. The four subtypes are: 1) Hypoxic subtype (Hypoxic, referred to as MUKDEN type I), ER pathway activation subtype (ER-activated, referred to as MUKDEN type II), immunomodulatory subtype (Immuno-modulatory, referred to as MUKDEN type III) and high heterogeneity subtype (High heterogeneity, referred to as MUKDEN type IV). The transcriptome characteristics of each subtype were revealed, and potential treatment options for each subtype were suggested. For example, MUKDEN type I is characterized by activation of the HIF-1 pathway and overexpression of the HER2 gene, suggesting that enhanced HER2 targeted therapy is beneficial to improving the pCR rate of type I patients; MUKDEN type II is characterized by activation of the estrogen receptor pathway, suggesting that enhanced endocrine therapy is beneficial to improving the pCR rate of type II patients; MUKDEN type III is characterized by activation of immune-related pathways, with highly expressed immune checkpoint molecules and high levels of tumor-infiltrating lymphocytes, suggesting that immune checkpoint blockers such as anti-PD-1 / PD-L1 monoclonal antibodies can be used for the treatment of type III patients; MUKDEN type IV has complex and diverse pathway characteristics, including tumor basal-like characteristics, stem cell characteristics and other pathways related to poor prognosis, suggesting that PI3K inhibitors such as Buparlisib, MEN1611, and Alpelisib can be used for the treatment of type IV patients. Molecular typing deeply reveals the heterogeneity of HR+ / HER2+ breast cancer and highlights the potential for precision treatment of HR+ / HER2+ breast cancer. Therefore, the present invention has significant clinical significance and great commercial value.

[0089] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. Gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer, It is characterized in that Including the following 4 genes: CD8A gene, KRT5 gene, GFRA1 gene and PFKP gene.

2. The gene composition according to claim 1, It is characterized in that The method for immunohistochemical typing of HR+ / HER2+ breast cancer is: CD8A positive, any KRT5, GFRA1 and PFKP expression: immunohistochemical MUKDEN type III; CD8A negative, KRT5 positive, any GFRA1 and PFKP expression: immunohistochemical MUKDEN type IV; CD8A negative, KRT5 negative, GFRA positive, any PFKP expression: immunohistochemical MUKDEN type II; CD8A negative, KRT5 negative, GFRA negative, PFKP negative expression: immunohistochemical MUKDENI type; Among them, CD8A positivity was defined as the percentage of CD8A-positive tumor cells in all cells ≥20%; KRT5 positivity was defined as the percentage of KRT5-positive tumor cells in all tumor cells ≥10%; GFRA positivity was defined as the percentage of GFRA-positive tumor cells in all tumor cells ≥10%; PFKP positivity was defined as the percentage of PFKP-positive tumor cells in all tumor cells ≥10%.

3. The method for screening the gene composition according to claim 1, It is characterized in that The gene combination is screened by the following steps: Step S1: Perform differential gene analysis between subtypes of HR+ / HER2+ breast cancer with mRNA expression profile data, identify highly expressed genes in each subtype, and perform preliminary screening of differential genes, including 70 MUKDEN I-specific genes, 95 MUKDEN II-specific genes, 388 MUKDEN III-specific genes, and 520 MUKDEN IV-specific genes; Step S2: using the mRNA expression data and mass spectrometry protein expression data from the Cancer Genome Atlas database, complete the Pearson correlation analysis between mRNA expression level and protein expression level; Step S3: Through KEGG pathway enrichment, select the gene sets enriched in the characteristic pathways in each subtype, and take the intersection of the gene sets with positive correlation between mRNA level and protein level in the Pearson correlation analysis results; Step S4: Literature research was conducted on the above intersection gene sets. PFKP gene and GFRA1 gene were selected as candidate characteristic genes for immunohistochemical testing for MUKDEN I and MUKDEN II subtypes, respectively. CD8A gene and KRT5 gene were selected for immunohistochemical testing for MUKDEN III and MUKDEN IV subtypes based on comprehensive consideration of pathway characteristics and clinical immunohistochemical antibody accessibility; Step S5: The gene combination finally screened out for immunohistochemical typing of HR+ / HER2+ breast cancer is CD8A gene, KRT5 gene, GFRA1 gene and PFKP gene.

4. The method for screening a gene composition according to claim 3, It is characterized in that In the step S1, the differential gene analysis between subtypes uses the Limma package of R language, and the initial screening of differential genes is based on Log2 (fold change) ≥ 1.0 and corrected P value < 0.05 as the standard.

5. The method for screening a gene composition according to claim 3, It is characterized in that In step S2, the Pearson correlation analysis uses the correlation coefficient ≥ 0.7 and the correlation test P value < 0.05 as the standard to further screen and filter the differentially expressed genes.

6. The method for screening a gene composition according to claim 3, It is characterized in that In step S3, among the characteristic pathways of each subtype, MUKDEN type I is specifically activated by the hypoxia pathway, MUKDEN type II is specifically activated by the estrogen receptor-related pathway, MUKDEN type III is prominent in tumor immune-related characteristics, and MUKDEN type IV is prominent in tumor stroma characteristics.

7. Use of the gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer according to claim 1 or claim 2 in the preparation of a HR+ / HER2+ breast cancer typing detection kit.

8. The use according to claim 7, It is characterized in that The kit comprises a biomarker, and the biomarker is a gene composition for immunohistochemical typing of HR+ / HER2+ breast cancer according to claim 1 or claim 2.

9. The use according to claim 8, It is characterized in that The biomarker is a nucleic acid, an oligonucleic acid chain, a PCR primer set or an antibody. Preferably, the biomarker is an antibody to the protein expressed by the gene composition.

10. Use of the kit according to any one of claims 7 to 9 in preparing a preparation for diagnosing HR+ / HER2+ breast cancer or predicting the prognosis of HR+ / HER2+ breast cancer.

Citation Information

Patent Citations

  • Gene group of molecular typing and distant metastasis risks of breast cancer, diagnostic product and application

    CN109385474A

  • Gene group for triple negative breast cancer immunohistochemical typing and application thereof

    CN115612740A

  • Machine learning disease prediction and treatment prioritization

    WO2020102043A1